If your gynecologist or endometriosis specialist has recommended Lupron or Orilissa, you’re being offered one of the most established medical treatments for endometriosis — and also one that comes with a real trade-off in side effects. Understanding how these medications actually work, what to expect in the first weeks, and how to judge whether one is working for you makes the decision, and the experience of being on it, considerably easier to navigate.
Key Takeaways
- Lupron (leuprolide) and Orilissa (elagolix) are both hormone therapies that lower estrogen to suppress endometriosis activity — they don’t remove existing lesions, but reduce the hormonal signal that drives their growth and inflammation
- Lupron is an injectable GnRH agonist that can cause a temporary symptom flare in the first 1–2 weeks before pain improves; Orilissa is a daily oral GnRH antagonist without that initial flare
- Both induce a temporary menopause-like state, with hot flashes, mood changes, and bone density loss being the most significant side effects to monitor
- Neither is typically used indefinitely — treatment duration is usually measured in months, sometimes extended with add-back hormone therapy
- Tracking your pain and symptom pattern before and after starting either medication is the most reliable way to know whether it’s actually working, since both drugs introduce their own side effects that can muddy the picture
How GnRH Therapies Work for Endometriosis
Endometriosis growth and inflammation are largely driven by estrogen. GnRH (gonadotropin-releasing hormone) therapies work by interrupting the hormonal signaling chain that leads to estrogen production, effectively putting the body into a temporary, medically induced low-estrogen state — similar to menopause. With less estrogen circulating, existing endometriosis implants receive less hormonal stimulation, which for many people reduces pain, bleeding, and inflammation.
It’s important to understand what these medications do not do: they don’t remove or shrink existing lesions the way surgery does, and symptoms typically return once the medication is stopped and normal hormone levels resume, unless combined with other treatment. They’re most often used to manage symptoms, shrink disease before surgery, or as a diagnostic tool (if symptoms improve significantly on GnRH therapy, that supports an endometriosis diagnosis).
Lupron (Leuprolide): How It Works and What to Expect
Lupron is a GnRH agonist, given by injection — typically monthly (Lupron Depot 3.75mg) or every three months (Lupron Depot 11.25mg).
The flare effect. Because Lupron initially stimulates the pituitary gland before suppressing it, many people experience a temporary worsening of symptoms in the first 1–2 weeks after starting — sometimes called a “flare” or “flare-up” phase. This is expected and typically resolves as the medication’s suppressive effect takes over, but it can be alarming if you aren’t warned about it in advance.
Timeline. After the initial flare phase, most people notice pain reduction beginning around week 3–4, with fuller effect by 8–12 weeks.
Common side effects. Hot flashes and night sweats (often the most disruptive day-to-day symptom), mood changes and irritability, vaginal dryness, headaches, and joint aches. With use beyond 6 months, bone mineral density loss becomes a more significant consideration, which is why many prescribers pair extended Lupron use with “add-back therapy” — a low dose of estrogen and progestin designed to ease side effects and protect bone density without fully reversing the suppressive effect on endometriosis.
Orilissa (Elagolix): How It Works and What to Expect
Orilissa is a GnRH antagonist, taken as a daily oral tablet in one of two doses (150mg once daily or 200mg twice daily).
No flare effect. Unlike Lupron, Orilissa suppresses the hormonal signal directly without an initial stimulating phase, so most people don’t experience the same early flare-up.
Dose-dependent suppression. The lower dose (150mg) provides partial estrogen suppression with a milder side-effect profile and is approved for longer-term use (up to 24 months). The higher dose (200mg twice daily) suppresses estrogen more completely — generally more effective for pain but with side effects closer to Lupron’s — and is approved for shorter courses (up to 6 months) due to greater bone density impact.
Common side effects. Hot flashes, headache, nausea, mood changes (including, in rare cases, more significant mood or anxiety symptoms that warrant prompt discussion with your prescriber), and irregular bleeding, particularly at the start of treatment.
Convenience factor. Because it’s an oral daily pill rather than an injection, some people find Orilissa easier to start and stop flexibly compared to a 3-month Lupron injection that can’t be “undone” once administered.
Lupron vs. Orilissa: Quick Comparison
| Lupron (leuprolide) | Orilissa (elagolix) | |
|---|---|---|
| Type | GnRH agonist | GnRH antagonist |
| Administration | Injection (monthly or every 3 months) | Daily oral tablet |
| Initial flare effect | Yes, first 1–2 weeks | No |
| Dose flexibility | Fixed per injection | Two dose options (150mg / 200mg) |
| Typical duration | Months, often with add-back therapy for longer use | Up to 24 months (low dose) or 6 months (high dose) |
| Reversibility | Effect persists until injection wears off | Effect reverses within days to weeks of stopping |
Neither is universally “better” — the right choice depends on your specific presentation, prior treatment history, and how you and your specialist weigh administration method, side-effect tolerance, and duration needs.
Tracking Whether It’s Actually Working
This is where things get genuinely confusing for a lot of people: both medications introduce their own side effects — hot flashes, mood shifts, headaches — that can make it hard to tell whether you feel different because your endometriosis is improving, or because you’re now dealing with medication side effects layered on top of it.
The way through that confusion is the same tool that helps with every other stage of managing endometriosis: a consistent, dated log of your pain and symptoms, started before you begin the medication and continued throughout.
Specifically worth tracking once you start either medication:
- Baseline pain score for at least 1–2 weeks before starting, so you have something concrete to compare against
- Daily pain score throughout treatment, using the same 0–10 scale
- Timing of any flare effect if you’re on Lupron, so you and your prescriber can distinguish the expected early flare from a lack of response
- New symptoms that might be side effects rather than endo symptoms — hot flashes, mood changes, headaches — logged separately from pain
- Bleeding pattern, particularly in the first weeks of Orilissa, when irregular bleeding is common
Comparing your tracked symptom trend from before starting treatment to your trend at 4, 8, and 12 weeks in gives you (and your prescriber) an objective answer to “is this working,” instead of a vague sense that things feel different. This is also exactly the kind of data that belongs in a doctor-ready report at a follow-up appointment — a clear before-and-after pain trend, plus any side effects worth discussing, moves the conversation toward the next decision (continue, switch, add back-add therapy, or move toward surgery) much faster than a general “I think it’s helping a bit.”
“Because GnRH therapies introduce their own side effects, the only reliable way to know whether Lupron or Orilissa is working is a tracked pain trend that started before you began treatment.”
What Happens After Stopping
Symptoms generally return once GnRH therapy is stopped and normal hormone levels resume, though the timeline varies — some people have a period of continued relief lasting weeks to months after stopping, while others notice symptoms return more quickly. This is a normal, expected part of how these medications work: they suppress activity while active, rather than curing the underlying disease.
For many people, GnRH therapy is used as one part of a broader plan — alongside pain management strategies, dietary approaches, or as a bridge to or from surgical treatment. Discussing what comes after a course of Lupron or Orilissa — whether that’s another medical option, surgery, or a maintenance approach — is worth raising with your specialist before you start, not just once the course ends.
Using EndoTracking Through Treatment
EndoTracking lets you log a medication start date and rate its effectiveness against your daily symptoms over time, so you can see — in a chart, not just a feeling — whether your pain score is trending down since starting Lupron or Orilissa, and whether any new symptoms line up with known side effects rather than a lack of treatment response. That comparison is exactly what most people wish they had clear evidence of at their 3-month follow-up.
Turn symptoms into a record you can use.
Log pain, cycle changes, medication response, and triggers in one endometriosis-specific tracker.
Start tracking on iPhoneiPhone · iOS 17+ · Core tracking is free; premium insights are optional
See the endometriosis symptom tracker app →Frequently Asked Questions
What is the difference between Lupron and Orilissa for endometriosis? Lupron (leuprolide) is a GnRH agonist given as an injection, typically monthly or every three months, and works by initially stimulating then suppressing the pituitary gland’s hormone signals. Orilissa (elagolix) is a GnRH antagonist taken as a daily oral pill and suppresses those signals more directly, without the initial hormone surge. Both ultimately lower estrogen to suppress endometriosis activity, but they differ in how they’re administered and their side-effect profile.
How long does it take for Lupron or Orilissa to work for endometriosis? Most people notice some reduction in pain within 4 to 8 weeks, though Lupron can cause a temporary symptom flare in the first 1–2 weeks (the “flare effect”) before pain improves. Full effect for both medications is generally assessed after 2–3 months of consistent use.
What are the main side effects of Lupron and Orilissa? Both induce a temporary menopause-like state due to lowered estrogen, causing hot flashes, night sweats, mood changes, vaginal dryness, and reduced bone density with extended use. Lupron’s side effects tend to be more pronounced due to the initial hormone flare and higher degree of suppression; Orilissa’s lower dose option has a milder side-effect profile, while the higher dose approaches Lupron’s intensity.
Can you stay on Lupron or Orilissa long-term? Neither is typically prescribed indefinitely due to bone density loss with prolonged low estrogen. Orilissa is FDA-approved for up to 24 months (lower dose) or 6 months (higher dose) with add-back therapy extending use. Lupron is often used in 3–6 month courses, sometimes with hormone add-back therapy to allow longer use while protecting bone density. Your prescriber will monitor duration based on your specific case.
How do I know if Lupron or Orilissa is actually working for my endometriosis? The clearest evidence is a tracked reduction in your usual pain score and symptom frequency compared to your baseline before starting the medication. Because both drugs take weeks to reach full effect and cause their own side effects that can be confused with continued endo symptoms, comparing a consistent pain log from before and after starting treatment is the most reliable way to tell whether it’s helping.
EndoTracking is a personal health tracking app. It does not provide medical advice or diagnosis. Consult a qualified healthcare provider for diagnosis and treatment, including before starting or stopping any prescription medication.